BE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody drug conjugate (iADCTM) products. NBE advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb DisplayTM technology for antibody discovery, its SMAC-TechnologyTM for site-specific payload conjugation of toxins to antibodies and a novel highly effective and immune-stimulatory anthracycline-based toxin platform.
31.08.2022
"You cannot do it alone" — Interview with Christian Elias Schneider of the Innovation Office at the University of Basel (venturelab.swiss)
18.01.2022
Billion-Franc deal without champagne (TOP 100)
10.12.2020
NBE Therapeutics makes a €1.18 billion exit (startupticker.ch)
10.12.2020
Boehringer Ingelheim acquiring NBE-Therapeutics for €1.18 billion (venturelab.swiss)
02.07.2018
07.06.2013
No Jobs
No videos and documents
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
The Venture Leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
CTI Start-up enables entrepreneurs to realize their innovative idea professionally.
In a process of three phases, over forty experienced coaches guide start-up companies on their way to enter the market successfully and attract financing. At the end of the coaching process, the most promising start-up companies have the opportunity to receive the prestigious CTI Start-up ’Label’. In addition, the companies benefit from the wide CTI Start-up network of industry experts, experienced entrepreneurs, business angels, venture capitalists and has access to foundations such as de Vigier, STI, FIT, Gebert, Rüf, etc.
Until today, CTI Start-up reviewed more than 1 800 projects, and awarded over 200 start-up enterprises with the CTI Start-up Label. Over 85% of these companies are still in business and some have shown remarkable growth, which is a sign that CTI Start-up guides them to sustainable success.
CTI also promotes the culture of entrepreneurship at universities, teaching hospitals, technical institutes as well as universities of applied sciences. CTI Entrepreneurship offers workshops to students on how to bring innovation to the market.
Website:
www.NBE-Therapeutics.com
Headquarter:
Basel
Foundation Date:
April 2012
Technology:
Sectors: